Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
25 Febbraio 2020 - 04:00PM
Business Wire
Pfizer Inc. (NYSE:PFE) invites investors and the general public
to listen to a webcast of a discussion with Charles Triano, Senior
Vice President, Investor Relations, at the Cowen and Company 40th
Annual Healthcare Conference on Tuesday, March 3, 2020 at 10:40
a.m. Eastern Standard Time.
To listen to the webcast, visit our web site at
www.pfizer.com/investors. Information on accessing and
pre-registering for the webcast will be available at
www.pfizer.com/investors beginning today.
Visitors will be able to listen to an archived copy of the
webcast at www.pfizer.com/investors.
Disclosure Notice: The webcast may include
forward-looking statements about, among other things, our
anticipated future operating and financial performance, business
plans and prospects, expectations for our product pipeline, in-line
products and product candidates, strategic reviews, capital
allocation objectives, business-development plans, benefits
anticipated from the reorganization of our commercial operations in
2019, plans for and prospects of our acquisitions and other
business development activities, including our proposed transaction
with Mylan N.V. (Mylan) to combine Upjohn and Mylan to create a new
global pharmaceutical company, Viatris, our acquisition of Array
BioPharma Inc. and our transaction with GSK which combined our
respective consumer healthcare businesses into a new consumer
healthcare joint venture, our ability to successfully capitalize on
growth opportunities or prospects, manufacturing and product supply
and plans relating to share repurchases and dividends, among other
things, that are subject to substantial risks and uncertainties
that could cause actual results to differ materially from those
expressed or implied by such statements. A description of these
risks and uncertainties can be found in Pfizer’s Annual Report on
Form 10-K for the fiscal year ended December 31, 2018 and in its
subsequent reports on Form 10-Q, including in the sections thereof
captioned “Risk Factors” and “Forward-Looking Information and
Factors That May Affect Future Results”, as well as in its
subsequent reports on Form 8-K, all of which are filed with the
U.S. Securities and Exchange Commission and available at
www.sec.gov and www.pfizer.com.
The forward-looking statements in the webcast speak only as of
the original date of the webcast. Pfizer assumes no obligation to
update forward-looking statements contained in the webcast as the
result of new information or future events or developments.
ADDITIONAL INFORMATION
This communication shall not constitute an offer to sell or the
solicitation of an offer to sell or the solicitation of an offer to
buy any securities, nor shall there be any sale of securities in
any jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. No offer of securities
shall be made except by means of a prospectus meeting the
requirements of Section 10 of the Securities Act of 1933, as
amended. In connection with the proposed combination of Upjohn Inc.
(“Newco”), a wholly owned subsidiary of Pfizer Inc. (“Pfizer”) and
Mylan N.V. (“Mylan”), which will immediately follow the proposed
separation of the Upjohn business (the “Upjohn Business”) from
Pfizer (the “proposed transaction”), Newco and Mylan have filed
certain materials with the Securities and Exchange Commission (the
“SEC”), including, among other materials, the registration
statement on Form S-4 which includes a proxy statement/prospectus
(as amended, the “Form S-4”), and Form 10 which includes an
information statement (as amended, the “Form 10”), each of which
has been filed by Newco with the SEC on October 25, 2019 and
subsequently refiled and/or amended. The registration statement on
Form S-4 became effective on February 13, 2020. On February 13,
2020, Newco filed a prospectus and Mylan filed a definitive proxy
statement with the SEC. A definitive proxy statement/prospectus was
sent to the Mylan shareholders seeking approval of the proposed
transaction on or about February 14, 2020. The registration
statement on Form 10 has not yet become effect. After the Form 10
is effective, a definitive information statement will be made
available to the Pfizer stockholders relating to the proposed
transaction. Newco and Mylan intend to file additional relevant
materials with the SEC in connection with the proposed transaction.
INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE DOCUMENTS
FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY
WILL CONTAIN IMPORTANT INFORMATION ABOUT MYLAN, NEWCO AND THE
PROPOSED TRANSACTION. The documents relating to the proposed
transaction (when they are available) can be obtained free of
charge from the SEC’s website at www.sec.gov. These documents (when
they are available) can also be obtained free of charge from Mylan,
upon written request to Mylan, at (724) 514-1813 or
investor.relations@mylan.com or from Pfizer on Pfizer’s internet
website at
https://investors.Pfizer.com/financials/sec-filings/default.aspx or
by contacting Pfizer’s Investor Relations Department at (212)
733-2323, as applicable.
PARTICIPANTS IN THE SOLICITATION
This communication is not a solicitation of a proxy from any
investor or security holder. However, Pfizer, Mylan, Newco and
certain of their respective directors and executive officers may be
deemed to be participants in the solicitation of proxies in
connection with the proposed transaction under the rules of the
SEC. Information about the directors and executive officers of
Pfizer may be found in its Annual Report on Form 10-K filed with
the SEC on February 28, 2019, its definitive proxy statement and
additional proxy statement relating to its 2019 Annual Meeting
filed with the SEC on March 14, 2019 and on April 2, 2019,
respectively, and Current Report on Form 8-K filed with the SEC on
June 27, 2019. Information about the directors and executive
officers of Mylan may be found in its amended Annual Report on Form
10-K filed with the SEC on April 30, 2019, and its definitive proxy
statement relating to its 2019 Annual Meeting filed with the SEC on
May 24, 2019. Additional information regarding the interests of
these participants can also be found in the Form S-4 and will also
be included in the definitive proxy statement of Mylan in
connection with the proposed transaction when it becomes available.
These documents (when they are available) can be obtained free of
charge from the sources indicated above.
About Pfizer: Breakthroughs That Change Patients’
Lives
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of health care
products, including innovative medicines and vaccines. Every day,
Pfizer colleagues work across developed and emerging markets to
advance wellness, prevention, treatments and cures that challenge
the most feared diseases of our time. Consistent with our
responsibility as one of the world's premier innovative
biopharmaceutical companies, we collaborate with health care
providers, governments and local communities to support and expand
access to reliable, affordable health care around the world. For
more than 150 years, we have worked to make a difference for all
who rely on us. We routinely post information that may be important
to investors on our website at www.Pfizer.com. In addition, to
learn more, please visit us on www.Pfizer.com and follow us on
Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us
on Facebook at Facebook.com/Pfizer.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200225005100/en/
Media Relations:
Patricia Kelly
+1 (212) 733-3810
Patricia.Kelly@Pfizer.com
Investor Relations:
Ryan Crowe +1 (212) 733-8160 Ryan.Crowe@Pfizer.com
Grafico Azioni Pfizer (NYSE:PFE)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Pfizer (NYSE:PFE)
Storico
Da Mar 2023 a Mar 2024